Potential of intestinal fatty acid binding protein (I-FABP) as a biomarker in ischemia and intestinal damage

Violation of mesenteric circulation and intestinal damage are life-threatening conditions that require early diagnosis and, if necessary, prompt surgical intervention. Currently, the diagnosis of these conditions remains a difficult task due to the nonspecific nature of clinical symptoms andlimitations of existing diagnostic tools. The aim of the study is to study the potential of intestinal fatty acid binding protein (I-FABP) as a biomarker of mesenteric circulatory disorders and intestinal damage. The article discusses the structure and function of I-FABP, its expression and distribution in the small intestine, the mechanisms of release of I-FABP. Clinical studies of I-FABP levels in patients with these conditions are analyzed, assessing the accuracy of diagnosis and potential thresholds. The results of this study show that I-FABP has significant potential as a biomarker of OMI, intestinal ischemia and intestinal damage. Elevated levels of I-FABP have been observed in patients, and the diagnostic accuracy of I-FABP appears to be superior to other currently used biomarkers. However, further research is needed to determine optimal thresholds and establish standardized I-FABP measurement protocols. Thus, the introduction of I-FABP as a biomarker into clinical practice may lead to earlier diagnosis and improved outcomes in patients with intestinal ischemia.

1. Acosta S, Björck M. Acute thrombo-embolic occlusion of the superior mesenteric artery: a prospective study in a well defined population. Eur J Vasc Endovasc Surg. 2003;26(2):179–183. https://doi.org/10.1053/ejvs.2002.1893.

2. Bagdasarov VV, Bagdasarova EA, Chernookov AI, Ramishvili VSh, Atayan AA, Yarkov SA. Tactics by the acute intestinal ischemia. Pirogov Russian Journal of Surgery. 2013;(6):44–50. (In Russ.) Available at: https://www.mediasphera.ru/issues/khirurgiya-zhurnal-im-n-i-pirogova/2013/6/030023-1207201368.

3. Klar E, Rahmanian PB, Bücker A, Hauenstein K, Jauch KW, Luther B. Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int. 2012;109(14):249–256. https://doi.org/10.3238/arztebl.2012.0249.

4. Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology. 2000;118(5):954–968. https://doi.org/10.1016/s0016-5085(00)70355-6.

5. Clair DG, Beach JM. Mesenteric Ischemia. N Engl J Med. 2016;374(10):959–968. https://doi.org/10.1056/NEJMra1503884.

6. Björck M, Koelemay M, Acosta S, Bastos Goncalves F, Kölbel T, Kolkman JJ et al. Editor’s Choice – Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53(4):460–510. https://doi.org/10.1016/j.ejvs.2017.01.010.

7. Leone M, Bechis C, Baumstarck K, Ouattara A, Collange O, Augustin P et al. Outcome of acute mesenteric ischemia in the intensive care unit: a retrospective, multicenter study of 780 cases. Intensive Care Med. 2015;41(4):667–676. https://doi.org/10.1007/s00134-015-3690-8.

8. Chernookov AI, Bozhedomov AYu, Atayan AA, Belykh EN, Silchuk ES, Khachatryan EO. New biomarkers of acute mesenteric ischemia. Novosti Khirurgii. 2018;26(3):358–365. (In Russ.) Available at: https://www.surgery.by/pdf/full_text/2018_3_11_ft.pdf.

9. Oldenburg WA, Lau LL, Rodenberg TJ, Edmonds HJ, Burger CD. Acute mesenteric ischemia: a clinical review. Arch Intern Med. 2004;164(10):1054–1062. https://doi.org/10.1001/archinte.164.10.1054.

10. Block T, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for intestinal ischaemia. Scand J Clin Lab Invest. 2008;68(3):242–248. https://doi.org/10.1080/00365510701646264.

11. Acosta S, Nilsson T. Current status on plasma biomarkers for acute mesenteric ischemia. J Thromb Thrombolysis. 2012;33(4):355–361. https://doi.org/10.1007/s11239-011-0660-z.

12. Montagnana M, Danese E, Lippi G. Biochemical markers of acute intestinal ischemia: possibilities andlimitations. Ann Transl Med. 2018;6(17):341. https://doi.org/10.21037/atm.2018.07.22.

13. Derikx JP, van Waardenburg DA, Thuijls G, Willigers HM, Koenraads M, van Bijnen AA et al. New Insight in Loss of Gut Barrier during Major Non-Abdominal Surgery. PLoS ONE. 2008;3(12):e3954. https://doi.org/10.1371/journal.pone.0003954.

14. Kanda T, Nakatomi Y, Ishikawa H, Hitomi M, Matsubara Y, Ono T, Muto T. Intestinal fatty acid-binding protein as a sensitive marker of intestinal ischemia. Dig Dis Sci. 1992;37(9):1362–1367. https://doi.org/10.1007/BF01296004.

15. Thuijls G, Derikx JP, van Wijck K, Zimmermann LJ, Degraeuwe PL, Mulder TL et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg. 2010;251(6):1174–1180. https://doi.org/10.1097/SLA.0b013e3181d778c4.

16. Schellekens DH, Grootjans J, Dello SA, van Bijnen AA, van Dam RM, Dejong CH et al. Plasma intestinal fatty acid-binding protein levels correlate with morphologic epithelial intestinal damage in a human translational ischemia-reperfusion model. J Clin Gastroenterol. 2014;48(3):253–260. https://doi.org/10.1097/MCG.0b013e3182a87e3e.

17. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, Glatz JF. Intestinal-type andliver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem. 2003;36(7):529–535. https://doi.org/10.1016/s0009-9120(03)00096-1.

18. Storch J, Thumser AE. Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem. 2010;285(43):32679–32683. https://doi.org/10.1074/jbc.R110.135210.

19. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005;352(1-2):15–35. https://doi.org/10.1016/j.cccn.2004.09.001.

20. Lieberman JM, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. Surgery. 1997;121(3):335–342. https://doi.org/10.1016/s0039-6060(97)90363-9.

21. Kanda T, Fujii H, Tani T, Murakami H, Suda T, Sakai Y et al. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology. 1996;110(2):339–343. https://doi.org/10.1053/gast.1996.v110.pm8566578.

22. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J Surg. 2009;33(7):1374–1383. https://doi.org/10.1007/s00268-009-0074-7.

23. Thuijls G, van Wijck K, Grootjans J, Derikx JP, van Bijnen AA, Heineman E et al. Early diagnosis of intestinal ischemia using urinary and plasma fatty acid binding proteins. Ann Surg. 2011;253(2):303–308. https://doi.org/10.1097/SLA.0b013e318207a767.

24. Matsumoto S, Sekine K, Funaoka H, Yamazaki M, Shimizu M, Hayashida K, Kitano M. Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia. Br J Surg. 2014;101(3):232–238. https://doi.org/10.1002/bjs.9331.

25. Kanda T, Tsukahara A, Ueki K, Sakai Y, Tani T, Nishimura A et al. Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. J Gastroenterol. 2011;46(4):492–500. https://doi.org/10.1007/s00535-011-0373-2.

26. Fuss J, Voloboyeva A, Polovyj V, Yaremkevych R. Intestinal fatty acid binding protein (I-FABP) as a marker for acute intestinal ischemia in patients with bowel obstruction. The Scientific Heritage. 2021;(78-2):31–33. https://doi.org/10.24412/9215-0365-2021-78-2-31-33.

27. Khavkin AI, Zhirnova SA, Novikova VP. The biological and clinical role of intestinal fatty acid-binding protein in clinical practice. Pediatric Nutrition. 2020;18(1):56–62. (In Russ.) https://doi.org/10.20953/1727-5784-2020-1-56-62.

28. Derikx JP, Vreugdenhil AC, Van den Neucker AM, Grootjans J, van Bijnen AA, Damoiseaux JG et al. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol. 2009;43(8):727–733. https://doi.org/10.1097/MCG.0b013e31819194b0.

29. Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatographytandem mass spectrometry. Neurogastroenterol Motil. 2009;21(7):734–e43. https://doi.org/10.1111/j.1365-2982.2009.01288.x.

30. Vermeulen Windsant IC, Hellenthal FA, Derikx JP, Prins MH, Buurman WA, Jacobs MJ, Schurink GW. Circulating intestinal fatty acidbinding protein as an early marker of intestinal necrosis after aortic surgery: a prospective observational cohort study. Ann Surg. 2012;255(4):796–803. https://doi.org/10.1097/SLA.0b013e31824b1e16.

31. Balaz P, Rokosny S, Bafrnec J. Mesenteric ischemia, new trends, diagnostic methods and algorithms to significantly reduce mortality and morbidity. Bratisl Lek Listy. 2013;114(3):158–165. https://doi.org/10.4149/bll_2013_035.

32. Cronk DR, Houseworth TP, Cuadrado DG, Herbert GS, McNutt PM, Azarow KS. Intestinal fatty acid binding protein (I-FABP) for the detection of strangulated mechanical small bowel obstruction. Curr Surg. 2006;63(5):322–325. https://doi.org/10.1016/j.cursur.2006.05.006.

33. Hong J, Gilder E, Blenkiron C, Jiang Y, Evennett NJ, Petrov MS et al. Nonocclusive mesenteric infarction after cardiac surgery: potential biomarkers. J Surg Res. 2017;211:21–29. https://doi.org/10.1016/j.jss.2016.12.001.

34. Gollin G, Marks C, Marks WH. Intestinal fatty acid binding protein in serum and urine reflects early ischemic injury to the small bowel. Surgery. 1993;113(5):545–551. Available at: https://www.surgjournal.com/article/0039-6060(93)90117-V/abstract.

35. Bodelier AG, Pierik MJ, Lenaerts K, de Boer E, Olde Damink SW, Hameeteman WM et al. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2016;28(7):807–813. https://doi.org/10.1097/MEG.0000000000000616.

36. Niemarkt HJ, de Meij TG, van de Velde ME, van der Schee MP, van Goudoever JB, Kramer BW et al. Necrotizing enterocolitis: a clinical review on diagnostic biomarkers and the role of the intestinal microbiota. Inflamm Bowel Dis. 2015;21(2):436–444. https://doi.org/10.1097/MIB.0000000000000184.

37. Kumar S, Wang J, Thomson AW, Gandhi CR. Hepatic stellate cells increase the immunosuppressive function of natural Foxp3+ regulatory T cells via IDO-induced AhR activation. J Leukoc Biol. 2017;101(2):429–438. https://doi.org/10.1189/jlb.2A0516-239R.

38. Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271–285. https://doi.org/10.1038/nrgastro.2012.57.

39. Pinheiro Mde B, Junqueira DR, Coelho FF, Freitas LG, Carvalho MG, Gomes KB, Dusse LM. D-dimer in preeclampsia: systematic review and meta-analysis. Clin Chim Acta. 2012;414:166–170. https://doi.org/10.1016/j.cca.2012.08.003.

40. Derikx JP, Schellekens DH, Acosta S. Serological markers for human intestinal ischemia: A systematic review. Best Pract Res Clin Gastroenterol. 2017;31(1):69–74. https://doi.org/10.1016/j.bpg.2017.01.004.

41. Peoc’h K, Nuzzo A, Guedj K, Paugam C, Corcos O. Diagnosis biomarkers in acute intestinal ischemic injury: so close, yet so far. Clin Chem Lab Med. 2018;56(3):373–385. https://doi.org/10.1515/cclm-2017-0291.

42. Dibirov MD, Gadzhimuradov RU, Bobylev AA, Sidorova DI, Fomin VS, Voitsekhovskaya EE. Prospects for improving laboratory diagnostics of disorders of mesenteric circulation. Moscow Surgical Journal. 2022;(1):99–104. (In Russ.) Available at: https://www.mossj.ru/jour/article/view/537.